Related Experiment Video
Updated: May 22, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation
Rodney B Luwor1, Xiaowen Chin, Andrew B McGeachie
1Department of Surgery (RMH/WH), University of Melbourne, Royal Melbourne Hospital, Parkville, Victoria, Australia.
Abstract:
Signalling from receptor tyrosine kinases is elicited by ligand binding which initiates the activation of many downstream signalling cascades. Endocytosis has been widely accepted as one mechanism in which cells inactivate signalling by internalising and subsequently degrading activated receptors. However, it is now evident that endocytosis of signalling receptors is important in initiation and sustaining downstream signalling. We and others have previously shown that epidermal growth factor receptor (EGFR) overexpression and activation of signal transducer and activator of transcription 3 (Stat3) are associated with tumourigenicity. Here, we examine the role of endocytosis in EGFR signal attenuation and differential signalling. Inhibition of dynamin II (Dyn II), a GTPase required for endocytosis, with a small molecular weight inhibitor, led to reduced EGF-mediated Stat3 phosphorylation and transcriptional activity in the A431 and HN5 human tumour cell lines. However, Dyn II inhibition had minimal effect on EGF-mediated EGFR and Erk1/2 phosphorylation, which is often regarded responsible for the tumourigenic function of the EGFR. Interestingly, this effect on Stat3 activation was not due to reduced EGFR/Stat3 association. Likewise, cells transfected with Dyn II siRNA or stably transfected with Dyn II shRNA had reduced EGF-mediated phospho-Stat3 levels but similar EGF-mediated phospho-EGFR and phospho-Erk1/2 levels compared with controls. Dyn II siRNA also reduced Stat3 transcriptional reporter activity and inhibits Stat3 accumulating into the nucleus. Taken together, our data suggest that the activation status of Stat3 and Erk1/2 and the sustainability of these signals are potentially due to the spatial and temporal control of the EGFR within the cell. This notion may have implications on therapeutic targeting and efficacy when using inhibitors to proteins either regulating endocytosis and/or signalling.
Insights
Endocytosis regulates epidermal growth factor receptor (EGFR) signaling. Inhibiting dynamin II (Dyn II) reduced Stat3 activation but not Erk1/2, suggesting spatial control of EGFR signaling impacts tumor cell activity.
Area of Science:
- Cell biology
- Molecular signaling
- Cancer research
Background:
- Receptor tyrosine kinases (RTKs) initiate signaling cascades upon ligand binding.
- Endocytosis was thought to inactivate signaling by receptor degradation.
- Emerging evidence highlights endocytosis's role in initiating and sustaining signaling.
Purpose of the Study:
- To investigate the role of endocytosis in epidermal growth factor receptor (EGFR) signal attenuation and differential signaling.
- To determine how dynamin II (Dyn II) inhibition affects downstream signaling pathways.
- To explore the implications for therapeutic targeting in cancer.
Main Methods:
- Inhibition of dynamin II (Dyn II) using a small molecular weight inhibitor.
- Utilized Dyn II siRNA and shRNA for gene silencing.
- Assessed EGF-mediated phosphorylation of EGFR, Stat3, and Erk1/2.
- Measured Stat3 transcriptional reporter activity and nuclear accumulation.
Main Results:
- Dyn II inhibition reduced EGF-mediated Stat3 phosphorylation and transcriptional activity.
- Dyn II inhibition minimally affected EGF-mediated EGFR and Erk1/2 phosphorylation.
- Dyn II inhibition did not alter EGFR/Stat3 association.
- Dyn II siRNA reduced Stat3 nuclear accumulation.
Conclusions:
- Endocytosis, regulated by Dyn II, differentially controls EGFR signaling pathways.
- Spatial and temporal regulation of EGFR by endocytosis influences Stat3 and Erk1/2 activation.
- These findings have implications for targeted cancer therapies involving endocytosis and signaling inhibitors.
Related Concept Videos
Amplifying Signals via Enzymatic Cascade
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
What are Second Messengers?

